KR100478347B1 - 메트포르민과 글리벤클라미드의 배합물을 포함하는 경구투여용 고형 제제 - Google Patents
메트포르민과 글리벤클라미드의 배합물을 포함하는 경구투여용 고형 제제 Download PDFInfo
- Publication number
- KR100478347B1 KR100478347B1 KR10-2000-7002714A KR20007002714A KR100478347B1 KR 100478347 B1 KR100478347 B1 KR 100478347B1 KR 20007002714 A KR20007002714 A KR 20007002714A KR 100478347 B1 KR100478347 B1 KR 100478347B1
- Authority
- KR
- South Korea
- Prior art keywords
- glybenclamide
- metformin
- less
- combination
- oral administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 title claims abstract description 84
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims abstract description 54
- 229960003105 metformin Drugs 0.000 title claims abstract description 32
- 239000007787 solid Substances 0.000 title claims abstract description 19
- 229960004580 glibenclamide Drugs 0.000 title claims description 13
- 239000006186 oral dosage form Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 239000002245 particle Substances 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 33
- 239000008187 granular material Substances 0.000 claims description 19
- 238000009472 formulation Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 3
- 239000007909 solid dosage form Substances 0.000 claims description 2
- 238000005550 wet granulation Methods 0.000 claims description 2
- 235000019988 mead Nutrition 0.000 abstract 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 19
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 229960004329 metformin hydrochloride Drugs 0.000 description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 10
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- 239000007888 film coating Substances 0.000 description 6
- 238000009501 film coating Methods 0.000 description 6
- 229940095884 glucophage Drugs 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229960001681 croscarmellose sodium Drugs 0.000 description 5
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229940123208 Biguanide Drugs 0.000 description 4
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 4
- 229940100389 Sulfonylurea Drugs 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229940127017 oral antidiabetic Drugs 0.000 description 4
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- -1 glypide Chemical compound 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 239000013066 combination product Substances 0.000 description 2
- 229940127555 combination product Drugs 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- YMCZETULMSWVBI-UHFFFAOYSA-N 2-(4-chlorophenoxy)acetic acid;3-(diaminomethylidene)-1,1-dimethylguanidine Chemical compound CN(C)C(=N)N=C(N)N.OC(=O)COC1=CC=C(Cl)C=C1 YMCZETULMSWVBI-UHFFFAOYSA-N 0.000 description 1
- ORKWMXWNOBMAJB-UHFFFAOYSA-N 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid;3-(diaminomethylidene)-1,1-dimethylguanidine Chemical compound CN(C)C(=N)N=C(N)N.CN(C)C(=N)N=C(N)N.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 ORKWMXWNOBMAJB-UHFFFAOYSA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008202 granule composition Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98401781A EP0974356B1 (en) | 1998-07-15 | 1998-07-15 | Tablets comprising a combination of metformin and glibenclamide |
| EP98401781.4 | 1998-07-15 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2004-7005583A Division KR20040053177A (ko) | 1998-07-15 | 1999-07-12 | 유효 용량의 메트포르민과 유효 용량의 글리벤클라미드를함유하는 경구투여용 단일 고형 제제를 포함하는 약학조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20010030603A KR20010030603A (ko) | 2001-04-16 |
| KR100478347B1 true KR100478347B1 (ko) | 2005-03-23 |
Family
ID=8235441
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2000-7002714A Expired - Lifetime KR100478347B1 (ko) | 1998-07-15 | 1999-07-12 | 메트포르민과 글리벤클라미드의 배합물을 포함하는 경구투여용 고형 제제 |
| KR10-2004-7005583A Ceased KR20040053177A (ko) | 1998-07-15 | 1999-07-12 | 유효 용량의 메트포르민과 유효 용량의 글리벤클라미드를함유하는 경구투여용 단일 고형 제제를 포함하는 약학조성물 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2004-7005583A Ceased KR20040053177A (ko) | 1998-07-15 | 1999-07-12 | 유효 용량의 메트포르민과 유효 용량의 글리벤클라미드를함유하는 경구투여용 단일 고형 제제를 포함하는 약학조성물 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US6303146B1 (enExample) |
| EP (4) | EP0974356B1 (enExample) |
| JP (2) | JP2002520371A (enExample) |
| KR (2) | KR100478347B1 (enExample) |
| CN (2) | CN1486698A (enExample) |
| AP (1) | AP1450A (enExample) |
| AR (2) | AR013052A1 (enExample) |
| AT (1) | ATE250418T1 (enExample) |
| AU (2) | AU753604B2 (enExample) |
| BR (1) | BR9906600A (enExample) |
| CA (1) | CA2303537C (enExample) |
| DE (1) | DE69818444T2 (enExample) |
| DK (1) | DK0974356T3 (enExample) |
| DZ (1) | DZ2846A1 (enExample) |
| ES (1) | ES2206868T3 (enExample) |
| ID (1) | ID25784A (enExample) |
| MA (1) | MA24930A1 (enExample) |
| MY (1) | MY129552A (enExample) |
| NZ (1) | NZ503248A (enExample) |
| OA (1) | OA11400A (enExample) |
| PT (1) | PT974356E (enExample) |
| RU (2) | RU2226396C2 (enExample) |
| SI (1) | SI0974356T1 (enExample) |
| TW (2) | TW555560B (enExample) |
| UY (1) | UY25611A1 (enExample) |
| WO (1) | WO2000003742A2 (enExample) |
| ZA (1) | ZA200001159B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220065960A (ko) * | 2020-11-13 | 2022-05-23 | 한국생산기술연구원 | 용해성 증대 및 취급용이성을 갖는 파우더 배지의 과립화 방법 |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| US20040102486A1 (en) * | 1998-11-12 | 2004-05-27 | Smithkline Beecham Corporation | Novel method of treatment |
| US6586438B2 (en) | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
| SK287810B6 (sk) | 1999-11-03 | 2011-10-04 | Bristol-Myers Squibb Company | Farmaceutický prostriedok obsahujúci nízkodávkovú kombináciu metformínu a glyburidu |
| US20010036479A1 (en) | 2000-01-14 | 2001-11-01 | Gillian Cave | Glyburide composition |
| FR2816840B1 (fr) | 2000-11-17 | 2004-04-09 | Flamel Tech Sa | Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation |
| FR2816841B1 (fr) * | 2000-11-22 | 2004-02-06 | Lipha | Nouvelles compositions pharmaceutiques a action antidiabetique et leur procede de preparation |
| MXPA03006217A (es) * | 2001-01-12 | 2004-10-15 | Sun Pharmaceutical Ind Ltd | Sistema de administracion espaciada de farmacos. |
| FR2825023B1 (fr) * | 2001-05-23 | 2005-04-15 | Flamel Tech Sa | Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif |
| US7767249B2 (en) * | 2001-06-07 | 2010-08-03 | Hewlett-Packard Development Company, L.P. | Preparation of nanoparticles |
| US20050271737A1 (en) * | 2001-06-07 | 2005-12-08 | Chinea Vanessa I | Application of a bioactive agent to a substrate |
| US8206753B2 (en) * | 2001-06-20 | 2012-06-26 | Metaproteomics, Llc | Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes |
| ATE378054T1 (de) * | 2001-07-30 | 2007-11-15 | Mitsubishi Pharma Corp | Mittel zu linderung von hyperglykämie nach dem essen |
| US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| ITFI20010230A1 (it) * | 2001-11-29 | 2003-05-29 | Menarini Int Operations Lu Sa | Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii |
| US7183321B2 (en) * | 2001-12-17 | 2007-02-27 | Bristol-Myers Squibb Company | Antidiabetic formulation and method |
| DE60219963T2 (de) * | 2002-01-25 | 2008-02-07 | Laboratorios Silanes, S.A. De C.V. | Pharmazeutische zusammensetzung, die zur glukosekontrolle im blut von patienten mit diabetes typ 2 eingesetzt wird |
| ES2377729T3 (es) * | 2002-02-21 | 2012-03-30 | Valeant International (Barbados) Srl | Formulaciones de liberación modificada de al menos una forma de tramadol |
| US20030187074A1 (en) * | 2002-03-04 | 2003-10-02 | Javed Hussain | Oral compositions for treatment of diabetes |
| US20030219482A1 (en) * | 2002-03-21 | 2003-11-27 | Chaudhari Sunil Sudhakar | Multiparticulate compositions for once-a-day administration |
| CN100577164C (zh) | 2002-04-09 | 2010-01-06 | 弗拉梅技术公司 | 可改进释放阿莫西林的微囊含水混悬液形式的口服药物制剂 |
| WO2003084518A2 (fr) | 2002-04-09 | 2003-10-16 | Flamel Technologies | Suspension orale de microcapsules de principes actifs |
| US8911781B2 (en) | 2002-06-17 | 2014-12-16 | Inventia Healthcare Private Limited | Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides |
| US7445796B2 (en) * | 2002-08-19 | 2008-11-04 | L. Perrigo Company | Pharmaceutically active particles of a monomodal particle size distribution and method |
| EP1562607A1 (en) * | 2002-11-15 | 2005-08-17 | Ranbaxy Laboratories, Ltd. | Pharmaceutical dosage forms of biguanide-sulfonylurea combinations |
| FR2853831A1 (fr) * | 2003-03-05 | 2004-10-22 | Usv Ltd | Forme posologique solide a usage oral de metformine et de glyburide et son procede de preparation |
| AU2004229285A1 (en) * | 2003-04-15 | 2004-10-28 | Chugai Seiyaku Kabushiki Kaisha | Remedy for diabetes |
| US20060121108A1 (en) * | 2004-12-02 | 2006-06-08 | Prasad C K | System and method for producing a directly compressible, high-potency formulation of metformin hydrochloride |
| CN100341495C (zh) * | 2004-12-29 | 2007-10-10 | 三九医药股份有限公司 | 格列本脲固体分散体、口服组合物及其制备方法 |
| KR100760430B1 (ko) * | 2004-12-31 | 2007-10-04 | 한미약품 주식회사 | 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법 |
| UY29445A1 (es) * | 2005-03-30 | 2006-10-02 | Generex Pharm Inc | Composiciones para la transmisión transmucosa oral de la metformina |
| US8529537B2 (en) * | 2005-08-05 | 2013-09-10 | Kimberly-Clark Worldwide, Inc. | Absorbent article with enclosures |
| MXPA05009633A (es) * | 2005-09-08 | 2007-03-07 | Silanes Sa De Cv Lab | Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada. |
| EP2452683A3 (en) | 2006-06-26 | 2012-08-22 | Amgen Inc. | Methods for treating atherosclerosis |
| WO2008062273A2 (en) * | 2006-11-20 | 2008-05-29 | Cadila Pharmaceuticals Limited | Solid oral dosage form having antidiabetic drug combination |
| AR067557A1 (es) | 2007-07-19 | 2009-10-14 | Takeda Pharmaceutical | Preparacion solida y metodo de preparacion |
| CN101855344B (zh) | 2007-07-26 | 2015-12-09 | 安姆根有限公司 | 修饰的卵磷脂-胆固醇酰基转移酶 |
| US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
| WO2011135106A1 (es) * | 2010-04-26 | 2011-11-03 | Smart Pharma Solutions, S.L | Granulado altamente dispersable para la preparación de formulaciones de sustancias activas de altas dosis y procedimiento de obtención del mismo |
| RU2451506C1 (ru) | 2011-06-02 | 2012-05-27 | Сергей Юрьевич Лешков | Комбинация для лечения сахарного диабета и его осложнений |
| AU2012347540A1 (en) | 2011-12-08 | 2014-06-26 | Amgen Inc. | Agonistic human LCAT antigen binding proteins and their use in therapy |
| EP2790729A4 (en) * | 2011-12-12 | 2015-08-12 | Orbis Biosciences Inc | PARTICULATE FORMULATIONS WITH DELAYED RELEASE |
| CN104127424A (zh) * | 2014-07-30 | 2014-11-05 | 沈阳药科大学 | 格列本脲衍生物及其制备方法和应用 |
| CN105030793A (zh) * | 2015-08-25 | 2015-11-11 | 瑞阳制药有限公司 | 二甲双胍格列本脲胶囊及其制备方法 |
| WO2019070109A1 (es) * | 2017-10-03 | 2019-04-11 | Infinite Clinical Research International, S.A. De C.V. | Triconjugado para el tratamiento de diabetes mellitus |
| WO2021196951A1 (zh) | 2020-04-01 | 2021-10-07 | 杭州中美华东制药有限公司 | Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法 |
| CN115461344B (zh) | 2020-04-01 | 2024-01-12 | 杭州中美华东制药有限公司 | 一种glp-1受体激动剂的晶型a及其制备方法 |
| CN113143940A (zh) * | 2020-12-30 | 2021-07-23 | 成都恒瑞制药有限公司 | 一种抗糖尿病药物组合物的制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997017975A1 (en) * | 1995-11-14 | 1997-05-22 | Abiogen Pharma S.R.L. | A glibenclamide-metformin combination for the treatment of diabetes mellitus of type ii |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE362704C (de) * | 1921-08-09 | 1922-11-02 | Naamlooze Vennootschap Interna | Vorrichtung zum Senken einer Last, insbesondere eines Rettungsbootes |
| US3174901A (en) | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| US4060634A (en) * | 1973-09-26 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Rapidly resorbable glibenclamide |
| DE2348334C2 (de) | 1973-09-26 | 1982-11-11 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs |
| US4916163A (en) | 1985-06-04 | 1990-04-10 | The Upjohn Company | Spray-dried lactose formulation of micronized glyburide |
| DE3833439A1 (de) | 1988-10-01 | 1991-09-12 | Hoechst Ag | Verfahren zur mikronisierung von glibenclamid |
| IE63463B1 (en) * | 1989-02-06 | 1995-04-19 | Zeneca Ltd | Phenylsulphone derivatives |
| GB9016978D0 (en) * | 1990-08-02 | 1990-09-19 | Ici Plc | Acetamide derivatives |
| DK36392D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
| DE4323636A1 (de) | 1993-07-15 | 1995-01-19 | Hoechst Ag | Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung |
| TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| AP1279A (en) | 1997-06-18 | 2004-05-20 | Smithkline Beecham Plc | Treatment of diabetes with thiazolidinedione and metformin. |
| US6544564B1 (en) * | 2001-11-27 | 2003-04-08 | Michael Donald Farley | Cytotoxic pharmaceutical composition |
-
1998
- 1998-07-15 DK DK98401781T patent/DK0974356T3/da active
- 1998-07-15 AT AT98401781T patent/ATE250418T1/de not_active IP Right Cessation
- 1998-07-15 SI SI9830517T patent/SI0974356T1/xx unknown
- 1998-07-15 EP EP98401781A patent/EP0974356B1/en not_active Revoked
- 1998-07-15 PT PT98401781T patent/PT974356E/pt unknown
- 1998-07-15 ES ES98401781T patent/ES2206868T3/es not_active Expired - Lifetime
- 1998-07-15 DE DE69818444T patent/DE69818444T2/de not_active Revoked
-
1999
- 1999-07-12 BR BR9906600-9A patent/BR9906600A/pt not_active Application Discontinuation
- 1999-07-12 RU RU2000109583/15A patent/RU2226396C2/ru active
- 1999-07-12 EP EP04008415A patent/EP1435240A3/en not_active Ceased
- 1999-07-12 AU AU54179/99A patent/AU753604B2/en not_active Expired
- 1999-07-12 EP EP99940114A patent/EP1011684A2/en not_active Ceased
- 1999-07-12 RU RU2003126257/15A patent/RU2286788C2/ru active
- 1999-07-12 ID IDW20000482D patent/ID25784A/id unknown
- 1999-07-12 NZ NZ503248A patent/NZ503248A/xx not_active IP Right Cessation
- 1999-07-12 WO PCT/EP1999/005571 patent/WO2000003742A2/en not_active Ceased
- 1999-07-12 CA CA002303537A patent/CA2303537C/en not_active Expired - Lifetime
- 1999-07-12 JP JP2000559876A patent/JP2002520371A/ja active Pending
- 1999-07-12 EP EP10185329A patent/EP2269613A3/en not_active Ceased
- 1999-07-12 KR KR10-2000-7002714A patent/KR100478347B1/ko not_active Expired - Lifetime
- 1999-07-12 CN CNA031092314A patent/CN1486698A/zh active Pending
- 1999-07-12 AP APAP/P/2000/001757A patent/AP1450A/en active
- 1999-07-12 CN CNB998013625A patent/CN1146427C/zh not_active Expired - Lifetime
- 1999-07-12 KR KR10-2004-7005583A patent/KR20040053177A/ko not_active Ceased
- 1999-07-13 MA MA25681A patent/MA24930A1/fr unknown
- 1999-07-14 MY MYPI99002968A patent/MY129552A/en unknown
- 1999-07-14 DZ DZ990146A patent/DZ2846A1/xx active
- 1999-07-14 TW TW088111959A patent/TW555560B/zh not_active IP Right Cessation
- 1999-07-14 US US09/353,141 patent/US6303146B1/en not_active Expired - Lifetime
- 1999-07-14 TW TW092113257A patent/TWI245632B/zh not_active IP Right Cessation
- 1999-07-15 AR ARP990103470A patent/AR013052A1/es not_active Application Discontinuation
- 1999-07-15 UY UY25611A patent/UY25611A1/es not_active Application Discontinuation
-
2000
- 2000-03-07 ZA ZA200001159A patent/ZA200001159B/xx unknown
- 2000-03-15 OA OA1200000076A patent/OA11400A/en unknown
-
2002
- 2002-12-27 US US10/329,426 patent/USRE38629E1/en not_active Expired - Lifetime
-
2003
- 2003-03-31 JP JP2003094873A patent/JP2003292443A/ja active Pending
- 2003-11-11 AU AU2003261560A patent/AU2003261560A1/en not_active Abandoned
-
2008
- 2008-04-07 AR ARP080101435A patent/AR065970A2/es not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997017975A1 (en) * | 1995-11-14 | 1997-05-22 | Abiogen Pharma S.R.L. | A glibenclamide-metformin combination for the treatment of diabetes mellitus of type ii |
Non-Patent Citations (1)
| Title |
|---|
| 약제학 책 제433-434면(한국약제학회 저, 문성사, 1985년 발행) * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220065960A (ko) * | 2020-11-13 | 2022-05-23 | 한국생산기술연구원 | 용해성 증대 및 취급용이성을 갖는 파우더 배지의 과립화 방법 |
| KR102484756B1 (ko) * | 2020-11-13 | 2023-01-06 | 한국생산기술연구원 | 용해성 증대 및 취급용이성을 갖는 파우더 배지의 과립화 방법 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100478347B1 (ko) | 메트포르민과 글리벤클라미드의 배합물을 포함하는 경구투여용 고형 제제 | |
| US5922769A (en) | Glibenclamide-metformin combination for the treatment of diabetes mellitus of type II | |
| CA2483199C (en) | High drug load tablet of imatinib | |
| US20030187074A1 (en) | Oral compositions for treatment of diabetes | |
| KR20040079898A (ko) | 메트포르민 및 글리벤클라미드를 포함하는 제 2형 당뇨병치료용 약제학적 조성물 | |
| US20060002998A1 (en) | Pharmaceutical dosage forms of biguanide-sulfonylurea combinations | |
| US20030224046A1 (en) | Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent | |
| US20040147564A1 (en) | Combinations of glimepiride and the thiazolidinedione for treatment of diabetes | |
| US20030219482A1 (en) | Multiparticulate compositions for once-a-day administration | |
| WO2006109175A2 (en) | Solid dosage form of an antidiabetic drug | |
| WO2004069229A1 (en) | Dual release anti-diabetic drugs and process of production thereof | |
| MXPA00002568A (en) | Solid oral dosage form comprising a combination of metformin and glibenclamide | |
| WO2004091587A1 (en) | Multiple release anti-diabetic drugs and process of production thereof | |
| OA12714A (en) | Solid oral dosage form comprising a combination ofmetformin and glibenclamide. | |
| HK1011525B (en) | A glibenclamide-metformin combination for the treatment of diabetes mellitus of type ii |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20000315 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20011123 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20040117 Patent event code: PE09021S01D |
|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20040416 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20040619 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20050126 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20050314 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20050315 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| G170 | Re-publication after modification of scope of protection [patent] | ||
| PG1701 | Publication of correction | ||
| PR1001 | Payment of annual fee |
Payment date: 20080219 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20090220 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20100302 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20110224 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20120223 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20130228 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20130228 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20140227 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140227 Start annual number: 10 End annual number: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20150225 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20150225 Start annual number: 11 End annual number: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20170227 Year of fee payment: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20170227 Start annual number: 13 End annual number: 13 |
|
| FPAY | Annual fee payment |
Payment date: 20180226 Year of fee payment: 14 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180226 Start annual number: 14 End annual number: 14 |
|
| EXPY | Expiration of term | ||
| PC1801 | Expiration of term |
Termination date: 20200112 Termination category: Expiration of duration |